鲍曼不动杆菌
微生物学
抗生素
多粘菌素
铜绿假单胞菌
阴沟肠杆菌
替加环素
生物
米诺环素
抗生素耐药性
金黄色葡萄球菌
肺炎克雷伯菌
细菌
大肠杆菌
遗传学
基因
生物化学
作者
Yonas A. Alamneh,Vlado Antonic,Brittany Garry,Michael J. Pucci,Rania Abu-Taleb,Jonathan P. Shearer,Samandra T. Demons,Derese Getnet,Brett E. Swierczewski,Troy Lister,Daniel V. Zurawski
出处
期刊:Antibiotics
[MDPI AG]
日期:2022-09-15
卷期号:11 (9): 1251-1251
标识
DOI:10.3390/antibiotics11091251
摘要
Antibiotic resistance, when it comes to bacterial infections, is not a problem that is going to disappear anytime soon. With the lack of larger investment in novel antibiotic research and the ever-growing increase of resistant isolates amongst the ESKAPEE pathogens (Enterobacter cloacae, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterococcus sp., and Escherichia coli), it is inevitable that more and more infections caused by extensively drug-resistant (XDR) and pandrug-resistant (PDR) strains will arise. One strategy to counteract the growing threat is to use antibiotic adjuvants, a drug class that on its own lacks significant antibiotic activity, but when mixed with another antibiotic, can potentiate increased killing of bacteria. Antibiotic adjuvants have various mechanisms of action, but polymyxins and polymyxin-like molecules can disrupt the Gram-negative outer membrane and allow other drugs better penetration into the bacterial periplasm and cytoplasm. Previously, we showed that SPR741 had this adjuvant effect with regard to rifampin; however, rifampin is often not used clinically because of easily acquired resistance. To find additional, appropriate clinical partners for SPR741 with respect to pulmonary and wound infections, we investigated tetracyclines and found a previously undocumented synergy with minocycline in vitro and in vivo in murine models of infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI